Lykos Therapeutics (formerly MAPS PBC)
Michael Mullette is a seasoned executive with extensive experience in the pharmaceutical industry. He has held various leadership roles at companies such as Moderna and Sanofi, where he has successfully managed commercial operations, market access, and business planning. Michael is known for his ability to build strong teams, negotiate with stakeholders, and drive strategic projects to success. He holds a Master of Business Administration from Lehigh University and a Bachelor of Business Administration from Villanova University.
Lykos Therapeutics (formerly MAPS PBC)
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.